CAR-T Cell Therapy in First Line for High Risk Diffuse Large B-Cell Lymphoma: Review of Efficacy and CostEffectiveness Against Standard of Care Chemo-Immunotherapy

被引：3
|
作者：
Akbar, Usman Ali [1 ]
Rashid, Zaraq [2 ]
Rehman, Zarlish [3 ]
Alam, Shehzad [4 ]
Altaf, Zooha [5 ]
Anwar, Rana Usman [6 ]
Khan, Adil [6 ]
Wakeel, Jafir [6 ]
Farooq, Saad [7 ]
Khan, Muhammad Haris [8 ]
Safi, Danish [9 ]
Inayat, Arslan [10 ]
Safi, Salah Ud Din [9 ]
机构：
[1] Northwell Hlth, Dept Internal Med, New York, NY USA
[2] LRH, Peshawar, Pakistan
[3] Hayatabad Med Complex, Peshwar, Pakistan
[4] Khyber Teaching Hosp, Peshawar, Pakistan
[5] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[6] Univ Louisville, Louisville, KY 40292 USA
[7] Nishtar Med Univ, Multan, Pakistan
[8] Univ Louisiana, Div Infect Dis, Shreveport, LA USA
[9] West Virginia Univ, Morgantown, WV 26506 USA
[10] Univ Buffalo, Buffalo, NY USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-170669
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：12052 / 12054
页数：3
相关论文
共 50 条
  • [1] The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
    Albanyan, Omar
    Chavez, Julio
    Munoz, Javier
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [2] The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
    Albanyan, Omar
    Chavez, Julio
    Munoz, Javier
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [3] Should CAR-T cell therapy be considered a standard of care for patients with refractory diffuse large B-cell lymphoma in second line treatment?
    Perez-Lamas, Lucia
    Sandoval-Sus, Jose
    Chavez, Julio C.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (02) : 139 - 148
  • [4] Relapsed or refractory diffuse large B-cell Lymphoma CAR-T Cell Therapy is superior to Standard Second-line Therapy
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (04) : 231 - 231
  • [5] CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis
    Shargian, Liat
    Raanani, Pia
    Yeshurun, Moshe
    Gafter-Gvili, Anat
    Gurion, Ronit
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (01) : E4 - E5
  • [6] Disparities in the Use of Chemo-Immunotherapy for Diffuse Large B-Cell Lymphoma in the United States
    Behringer, Karolin
    Mueller, Horst
    Flechtner, Hans-Henning
    Brillant, Corinne
    Halbsguth, Teresa
    Schober, Thomas
    Nisters-Backes, Hiltrud
    Engert, Andreas
    Borchmann, Peter
    BLOOD, 2009, 114 (22) : 370 - 370
  • [7] CAR-T THERAPY IN PATIENTS WITH LARGE B-CELL DIFFUSE LYMPHOMA: EXPERIENCE OF A CENTER
    Martin Lopez, A. A.
    Lopez Corral, L.
    Perez Lopez, E.
    Prieto Garcia, L.
    Cabero Martinez, A.
    Garcia Blazquez, M.
    Lopez Parra, M.
    Alana Garcia, M.
    Albala Martinez, N.
    Tamayo Alonso, P.
    Diaz Gonzalez, L.
    Arias Rodriguez, P.
    Blanco Munez, O.
    Esteban Velasco, C.
    Yeguas Bermejo, A.
    Martin Martin, L.
    Orfao, A.
    Gutierrez Gutierrez, N.
    Caballero Barrigon, D.
    Martin Garcia-Sancho, A.
    HAEMATOLOGICA, 2021, 106 (10) : 56 - 57
  • [8] ROLE OF CAR-T CELLS THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Sen, P.
    Saadeh, B.
    Loh, E.
    VALUE IN HEALTH, 2019, 22 : S440 - S441
  • [9] The intrinsic defects of T cells impact the efficacy of CAR-T therapy in patients with diffuse large B-cell lymphoma
    Zhao, Jinrong
    Wei, Chong
    Wang, Shuqing
    Zhang, Yan
    Wang, Wei
    Zhao, Danqing
    Wang, Zi
    Zhou, Zhipeng
    Bai, Jing
    Zhang, Wei
    Zhou, Daobin
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [10] The intrinsic defects of T cells impact the efficacy of CAR-T therapy in patients with diffuse large B-cell lymphoma
    Jinrong Zhao
    Chong Wei
    Shuqing Wang
    Yan Zhang
    Wei Wang
    Danqing Zhao
    Zi Wang
    Zhipeng Zhou
    Jing Bai
    Wei Zhang
    Daobin Zhou
    Blood Cancer Journal, 13
12345